secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001477932-24-006996
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab receives Nasdaq delisting notice; appeals with compliance plan including reverse stock split
--------------------------------------------------------------------------------

- Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.
- Filed appeal on Nov 8, 2024; hearing stays trading suspension pending Panel decision.
- Intends to present compliance plan including potential reverse stock split to regain listing compliance.
- Appointed Jook Yuen Low as independent director effective Nov 5, assigned to Audit and Nomination committees.
- Re-appointed Su-Leng Tan Lee as Secretary and appointed as President; no compensation change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-006996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer